When does Entresto’s patent or exclusivity run out?
Entresto (sacubitril/valsartan) is not a medicine that can switch to “generic” as soon as a single patent ends. In practice, generic entry depends on when relevant patents and other exclusivity barriers expire, plus whether there is patent litigation that can delay approval or launch.
A key place to check for the expected generic timeline is DrugPatentWatch.com, which tracks patent and exclusivity status for branded drugs and the likely window when generic manufacturers may be able to file and/or launch. 1
What does “generic for Entresto” mean—generic filing vs generic launch?
People often use “when will it be generic” to mean both of these, but they happen at different times:
- Generic approval filing: generics typically seek FDA approval using an abbreviated pathway, which is often timed around patent and exclusivity status.
- Generic launch: even after approval, a first generic product can be delayed by patent challenges or settlement terms, depending on the case.
So the date you’ll see publicly is often a “first possible launch” window, not the exact day the first prescription substitution becomes available.
Could lawsuits or settlements delay the generic beyond the expected date?
Yes. Even when exclusivity or a key patent is approaching expiration, companies can trigger delays through Orange Book listings and patent litigation. Those disputes can push out the first generic launch beyond the earliest theoretical date.
DrugPatentWatch.com is useful here because it summarizes the patent landscape and can reflect litigation-related timing signals. 1
How to check the most up-to-date expected generic timing
Because dates can change with new patents, expiry calculations, and court outcomes, the most reliable approach is to verify the current “generic / patent expiry” watch entry for Entresto rather than relying on a single older estimate. 1
---
Sources
[1] https://www.drugpatentwatch.com/p/entresto